Global Market: Taiwan

Taiwan is ranked among the top 25 MedTech global market in terms of value. According to the International Trade Association, a major market for US medical device export that accounts for about 33% market share.

Population (24’): 23.4 million (ITA) GDP per Capital: $37,827 (IMF)

Life Expectancy: 80.9 yrs Currency: New Taiwan Dollar NT$

MedTech Maturity level: Mature, Highly advanced

Population Dynamics: Aging, Low birth rate “supper-aged society”

Health System Structure

• Governance model: Established in 1995 the Taiwan National Health Insurance (NHI), a universal and mandatory single payer system for all citizens and foreigners residing in Taiwan for 6months or longer. With 99.0- 99.9% of its population covered.

  Government-run, NHI is administered by the National Health Insurance Administration (NHIA) under the Ministry of Health and Welfare (MoHW). Funded by revenue from payroll-based premiums, supplementary premiums from non-payroll income( large bonuses, professional fees, wages from second and third jobs, income from dividend, interest and rent) and the rest from tobacco tax and lottery gains.
  

• Coverage model: The National Health Insurance (NHI) program offers a broad and inclusive benefit package, spanning inpatient and outpatient care, dental services, traditional Chinese medicine, and prescription drugs. Funding for the hospital sector is allocated prospectively each year through a global budget system, which sets the total expenditure ceiling in advance.

  Alongside NHI, disease‑specific cash indemnity private insurance products are available. These policies provide patients with a fixed cash payment that can be used for services not covered by NHI and typically in private hospitals. However, they do not reimburse services already included in the NHI benefit package, nor do they provide faster access to care.

• Procurement pathways: Private hospital purchase MedTech devices from local distributors with whom they already have established commercial relationships. While tenders for public hospitals are handled through the Taiwan’s government procurement system and awarded according to formal bidding procedures.

Reimbursement Environment

• Reimbursement mechanisms: Once a medical device has received approval from Taiwan FDA (TFDA), an application must be submitted to NHIA before selling devices to the market. The application should include; basic product information, budget impact, clinical evidence or type of surgery, and others. NHIA sets pricing and reimbursement fro medical devices functional category system. Payment system is a combination of fee-for-service, balance-billing system, and Taiwan Diagnosis-Related Groups (Tw-DRG).

  When a medical device fall into fee-for-service or Tw-DRG, NHI covers the full cost, however under balanced billing NHI covers only part of the price and the patient pays the rest. To qualify for balanced billing, devices must demonstrate greater durability, superior clinical efficacy, and improved procedural convenience.

  Some manufacturers intentionally keep their products in the self‑pay market as a faster route to adoption. For premium medical devices, the private/self‑pay segment often represents the most attractive profit pool, offering higher prices and fewer constraints than NHI reimbursement. Price variability in this channel is substantial, shaped by local distributor–hospital relationships, hospital positioning, competitive dynamics, and patients’ willingness to pay. Despite it’s commercial potential, the self‑pay market is also characterized by limited price transparency, affordability challenges, and cultural norms that discourage negotiation while encouraging families to pursue what they perceive as the best possible care.

• HTA maturity: High - Any product seeking reimbursement under Taiwan’s global budget system must undergo formal HTA review. Taiwan only accepts evidence published in peer‑reviewed journals, making it essential that economic value claims are grounded in rigorously reviewed, peer‑validated data.

• Pricing controls: Taiwan’s most powerful cost containment measure is the prospective Global Budget that puts a limit on spend. so far it has had a significant impact on overall healthcare spending growth.

• Time to reimbursement: Reimbursement timelines in Taiwan can be lengthy, often stretching over several years before a medical device achieves full NHI coverage. The duration varies widely across different non‑reimbursed categories, reflecting differences in evidence requirements, coding pathways, and NHIA prioritization.

• Coding classification: Functional Category system

Value Drivers for Medical Technology

• Clinical and Economic evidence expectations: Enhanced clinical efficacy, greater safety for users, improved treatment procedures, invasiveness reduction, cost savings, ease of use and treatment for patient with rare disease are considered when it comes to premium reimbursement.

• Innovation appetite: High -Taiwan has a robust biotech industry supported by strong R&D and skilled talent.

• Local manufacturing incentives: Taiwan remains a competitive producer of mid‑ to low‑end medical equipment. Government‑backed investment in the local industry has continued to grow since the initiative launched in 2017.

• Digital readiness: Ready and Ahead - Taiwanese government continues to actively support AI-driven health solutions and smart manufacturing.

Population & Demographic Baseline

• Population size: 23.4 million (ITA)

• Age distribution: 19% aged 65+

• Disease burden: According to the 25’-26’ NHI report,there is about 8.5 million people with chronic disease

• Healthcare spend per capital (20’): $3,047

• Healthcare workforce density (20’):

  • Practicing Physicians per 1,000: 1.7

  • Nurses per 1,000: 5.7

  • Hospital beds per 1,000: 5.7

Economic Standing

Past

• GDP growth patterns: Stable growth

• Healthcare spending as % of GDP: 6-8%

• Import vs local production trends: High demand for high end medical device import

Present

• Current GDP and stability (25) IMF: 884.39 Billion, stable

• Healthcare budget priorities: Curbing cost, improving access, system wide efficiencies, expansion of self-pay and co payment

• Biotechnology market size in US $ millions (25’ estimates):

  • Total Export: 4,068

  • Total Import: 7,003

  • Imports from the US: 1,399

Future

• Demographic pressure scenarios: “Supper-aged society”. To support the island’s aging population, the government is actively promoting regenerative medicine, precision medicine and digital health solution to address health care demands.

• Expected policy changes: NHI policy could shift towards increased co-payments and larger self-pay market to help contain rising healthcare costs.

• Digital transformation outlook: Taiwan’s government is fully committed to the 2030 All‑Age Precision Health Vision. Leveraging its strong capabilities in information and communications technology, Taiwan is well positioned to integrate innovative medical technologies into its health system

Regional Opportunity & Risk Summary

• Market attractiveness drivers: Foreign imports are still in high demand with priority on innovative medical technology. Taiwan continue to harmonize its regulatory standards to match international standards presenting a smoother approval process.
  

• Key barriers to product entry: Taiwan’s price‑sensitive environment and extended reimbursement timelines pose real challenges for new entrants.
  

Strategic Market Entry Recommendations

• Cultivate the right partnerships - local distributor with a great network, clinical experts and medical societies. These partnerships are key to successful market entry , creation of new categories or getting full reimbursement.

• Medical devices covered by NHI have continued to gradually increase while manufacturers’ prices at launch are increasing. This means that reimbursement policy and pricing must evolve with the market.

• Given long reimbursement timelines, entering through the self‑pay channel can accelerate adoption, but it is a highly variable, loosely regulated market that demands disciplined pricing and navigation.

• Economic evidence such as budget impact models (BIMs), cost effective analysis (CEA), and resource use analysis that have local applicability to the Taiwan population and health system are extremely useful for reimbursement. Localized economic data strengthens credibility with NHIA, aligns with Taiwan’s requirement for peer‑reviewed evidence, and increases the likelihood that value claims will be accepted during reimbursement review.
  

Overall, Taiwan’s price sensitivity and long reimbursement timelines make the self‑pay market an important pathway for early adoption. Companies that navigate this channel effectively can establish presence and momentum while preparing for the slower NHI reimbursement process.